Neo Ivy Capital Management Invests $3.36 Million in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Neo Ivy Capital Management acquired a new position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 130,806 shares of the company's stock, valued at approximately $3,361,000. Neo Ivy Capital Management owned 0.15% of IDEAYA Biosciences at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. FMR LLC grew its position in IDEAYA Biosciences by 2.6% during the 4th quarter. FMR LLC now owns 12,963,151 shares of the company's stock worth $333,153,000 after acquiring an additional 327,498 shares during the last quarter. Janus Henderson Group PLC lifted its position in IDEAYA Biosciences by 13.5% in the fourth quarter. Janus Henderson Group PLC now owns 5,857,639 shares of the company's stock valued at $150,606,000 after purchasing an additional 695,263 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of IDEAYA Biosciences by 5.9% during the fourth quarter. Vanguard Group Inc. now owns 5,078,084 shares of the company's stock valued at $130,507,000 after purchasing an additional 282,936 shares during the period. Deerfield Management Company L.P. Series C boosted its stake in shares of IDEAYA Biosciences by 5.5% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,736,000 shares of the company's stock valued at $70,315,000 after purchasing an additional 142,000 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of IDEAYA Biosciences by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 1,988,681 shares of the company's stock worth $51,121,000 after purchasing an additional 43,226 shares during the last quarter. Hedge funds and other institutional investors own 98.29% of the company's stock.

Analyst Ratings Changes

IDYA has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. upped their price target on shares of IDEAYA Biosciences from $63.00 to $66.00 and gave the company an "overweight" rating in a report on Thursday, May 22nd. Stephens reaffirmed an "overweight" rating and set a $50.00 price objective on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $54.27.

IDEAYA Biosciences Price Performance

IDYA stock traded up $0.32 during trading on Wednesday, reaching $19.74. The company had a trading volume of 352,318 shares, compared to its average volume of 1,003,446. IDEAYA Biosciences, Inc. has a 52 week low of $13.45 and a 52 week high of $44.42. The company has a market cap of $1.73 billion, a P/E ratio of -5.99 and a beta of 0.26. The business has a 50 day moving average of $17.68 and a 200 day moving average of $21.70.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period in the previous year, the firm posted ($0.53) earnings per share. Research analysts expect that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.